Table 3.

Local recurrence and local–regional recurrence according to combinations of patient age and the 21-gene recurrence score

Group	No. of patients	Local recurrence		P value	Local–regional recurrence		P value
		At 5 years % (95 % CI)	At 10 years % (95 % CI)		At 5 years % (95 % CI)	At 10 years % (95 % CI)
Overall
Age <50				0.29			0.23
Low RS	21	0	1.9 (0.5–7.9)		0	2.0 (0.5–7.9)
Intermediate RS	26	8.1 (3.4–19.6)	8.1 (3.4–19.6)		8.1 (3.4–19.6)	8.1 (3.4–19.6)
High RS	123	3.8 (2.1–7.2)	8.3 (4.5–15.6)		4.9 (2.8–8.5)	9.4 (5.3–16.5)
Age ≥ 50				0.49			0.60
Low RS	66	1.4 (0.3–5.4)	3.4 (1.0–12.2)		1.4 (0.3–5.4)	4.2 (1.4–12.5)
Intermediate RS	41	0	0		0	3.5 (0.5–22.9)
High RS	111	3.8 (1.9–7.6)	6.8 (3.2–14.4)		4.9 (2.7–9.0)	7.9 (4.1–15.4)
Subset of HR positive tumors
Age <50				0.17			0.09
Low RS	21	0	1.9 (0.5–7.9)		0	2.0 (0.5–7.9)
Intermediate RS	26	8.1 (3.4–19.6)	8.1 (3.4–19.6)		8.1 (3.4–19.6)	8.1 (3.4–19.6)
High RS	29	8.0 (3.7–17.3)	10.3 (5.4–19.7)		10.1 (5.2–19.4)	12.4 (7.0–21.9)
Age ≥ 50				0.52			0.57
Low RS	65	1.4 (0.3–5.5)	3.5 (1.0–12.3)		1.4 (0.3–5.5)	4.3 (1.4–12.7)
Intermediate RS	41	0	0		0	3.5 (0.5–22.9)
High RS	37	4.3 (1.6–11.9)	9.9 (3.2–30.7)		5.8 (2.7–12.3)	11.2 (4.2–29.9)

RS recurrence score (i.e., 21-gene recurrence score), HR hormone receptor